Cyrus Sold Protein Software to 120 Drugmakers. Then It Put Its Own Molecules on the Line.

The Seattle spinout made Rosetta easier for pharma scientists, learned from more than 30 partnered discovery programs, and then made a riskier bet: building its own autoimmune drugs. Its story is a useful lesson in when software should become a laboratory - and when that strategy can still fail.